S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
This is a buy-the-dip opportunity in Zscaler
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
This is a buy-the-dip opportunity in Zscaler
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
This is a buy-the-dip opportunity in Zscaler
S&P 500   4,554.89
DOW   35,416.98
QQQ   390.19
Alibaba is down more than 10% since earnings, now what?
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
5 stocks for the Christmas wishlist: Hoping for a pullback
Lemonade nears breakout, short interest surges, analysts bearish
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
ULTA stock is setting up to swing for the fences
Get ready for Christmas shopping-sprees with these 2 winners
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Charlie Munger, who helped Warren Buffett build investment powerhouse Berkshire Hathaway, dies at 99
This is a buy-the-dip opportunity in Zscaler

Jazz Pharmaceuticals Stock Price, News & Analysis (NASDAQ:JAZZ)

$114.49
-3.05 (-2.59%)
(As of 11/28/2023 ET)
Compare
Today's Range
$111.25
$117.21
50-Day Range
$114.49
$136.00
52-Week Range
$111.25
$160.96
Volume
1.52 million shs
Average Volume
715,410 shs
Market Capitalization
$7.21 billion
P/E Ratio
130.10
Dividend Yield
N/A
Price Target
$194.86

Jazz Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
70.2% Upside
$194.86 Price Target
Short Interest
Healthy
4.08% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.33mentions of Jazz Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$236,748 Sold Last Quarter
Proj. Earnings Growth
13.50%
From $15.41 to $17.49 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.74 out of 5 stars

Medical Sector

116th out of 949 stocks

Pharmaceutical Preparations Industry

39th out of 440 stocks


JAZZ stock logo

About Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, such as hematologic and solid tumors. Its lead marketed products in neuroscience include Xywav, an oral solution for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients with narcolepsy and idiopathic hypersomnia (IH); Xyrem, a sodium oxybate oral solution for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older; and Epidiolex, a cannabidiol oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex in patients one year of age or older. The company's lead marketed products in oncology comprise Zepzelca for the treatment of adult patients with metastatic small cell lung cancer; Rylaze, a product for use as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adults and pediatric patients aged one month or older who has developed hypersensitivity to E. coli-derived asparaginase; Vyxeos, a liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation. It has licensing and collaboration agreements with Zymeworks Inc.; Sumitomo Pharma Co., Ltd; Werewolf Therapeutics, Inc.; Codiak BioSciences, Inc.; Ligand Pharmaceuticals Incorporated; XL-protein GmbH; and Redx Pharma plc. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

JAZZ Stock Price History

JAZZ Stock News Headlines

UBS Downgrades Jazz Pharmaceuticals (JAZZ)
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
5 Best Upside Stocks To Buy Now
Jazz global licensing deal swings IP Group shares
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
See More Headlines
Receive JAZZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Jazz Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/09/2021
Today
11/29/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/06/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:JAZZ
CUSIP
G5087110
Employees
2,800
Year Founded
2003

Price Target and Rating

Average Stock Price Target
$194.86
High Stock Price Target
$225.00
Low Stock Price Target
$135.00
Potential Upside/Downside
+70.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

Net Income
$-224,060,000.00
Pretax Margin
-2.73%

Debt

Sales & Book Value

Annual Sales
$3.66 billion
Cash Flow
$21.52 per share
Book Value
$55.42 per share

Miscellaneous

Free Float
60,187,000
Market Cap
$7.21 billion
Optionable
Optionable
Beta
0.73

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report














JAZZ Stock Analysis - Frequently Asked Questions

Should I buy or sell Jazz Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Jazz Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" JAZZ shares.
View JAZZ analyst ratings
or view top-rated stocks.

What is Jazz Pharmaceuticals' stock price target for 2024?

8 equities research analysts have issued 12-month price targets for Jazz Pharmaceuticals' stock. Their JAZZ share price targets range from $135.00 to $225.00. On average, they predict the company's stock price to reach $194.86 in the next year. This suggests a possible upside of 70.2% from the stock's current price.
View analysts price targets for JAZZ
or view top-rated stocks among Wall Street analysts.

How have JAZZ shares performed in 2023?

Jazz Pharmaceuticals' stock was trading at $159.31 at the start of the year. Since then, JAZZ stock has decreased by 28.1% and is now trading at $114.49.
View the best growth stocks for 2023 here
.

Are investors shorting Jazz Pharmaceuticals?

Jazz Pharmaceuticals saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 2,570,000 shares, a decline of 6.2% from the October 31st total of 2,740,000 shares. Based on an average daily trading volume, of 644,000 shares, the short-interest ratio is presently 4.0 days.
View Jazz Pharmaceuticals' Short Interest
.

When is Jazz Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our JAZZ earnings forecast
.

How were Jazz Pharmaceuticals' earnings last quarter?

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) posted its earnings results on Tuesday, November, 9th. The specialty pharmaceutical company reported $4.20 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.60 by $1.60. The specialty pharmaceutical company had revenue of $838.12 million for the quarter, compared to analysts' expectations of $829.98 million. Jazz Pharmaceuticals had a net margin of 2.11% and a trailing twelve-month return on equity of 22.23%. During the same period in the previous year, the company posted $3.86 EPS.

What guidance has Jazz Pharmaceuticals issued on next quarter's earnings?

Jazz Pharmaceuticals issued an update on its FY23 earnings guidance on Wednesday, November, 8th. The company provided earnings per share guidance of $18.15-$19.00 for the period, compared to the consensus earnings per share estimate of $18.66. The company issued revenue guidance of $3.75-$3.875 billion, compared to the consensus revenue estimate of $3.83 billion.

What is Bruce C. Cozadd's approval rating as Jazz Pharmaceuticals' CEO?

60 employees have rated Jazz Pharmaceuticals Chief Executive Officer Bruce C. Cozadd on Glassdoor.com. Bruce C. Cozadd has an approval rating of 92% among the company's employees. This puts Bruce C. Cozadd in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Jazz Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jazz Pharmaceuticals investors own include Ligand Pharmaceuticals (LGND), Gilead Sciences (GILD), Alibaba Group (BABA), Micron Technology (MU), NVIDIA (NVDA), Netflix (NFLX), Tesla (TSLA), AbbVie (ABBV), Bank of America (BAC) and Biogen (biib).

Who are Jazz Pharmaceuticals' major shareholders?

Jazz Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LSV Asset Management (3.76%), JPMorgan Chase & Co. (2.26%), FMR LLC (2.12%), Ameriprise Financial Inc. (2.06%), Polaris Capital Management LLC (1.97%) and Morgan Stanley (1.30%). Insiders that own company stock include Anne Oriordan, Bruce C Cozadd, Bruce C Cozadd, Christopher J Tovey, Elmar Schnee, Finbar Larkin, James E Flynn, Jennifer E Cook, Kenneth W O'keefe, Kim Sablich, Mark Douglas Smith, Neena M Patil, Patricia Carr, Patrick G Enright, Peter Gray, Renee D Gala, Rick E Winningham, Robert Iannone and Samantha Pearce.
View institutional ownership trends
.

How do I buy shares of Jazz Pharmaceuticals?

Shares of JAZZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

Does Jazz Pharmaceuticals have any subsidiaries?
The following companies are subsidiares of Jazz Pharmaceuticals: Cavion.
Read More
This page (NASDAQ:JAZZ) was last updated on 11/29/2023 by MarketBeat.com Staff

My Account -